The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Open accessAbstract
This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by the European LeukemiaNet (ELN) consortium. Recommendations were produced by multiple-step formalized procedures of group discussion. A critical appraisal of evidence by using Grades of Recommendation, Assessment, Development and Evaluation (GRADE) methodology was performed in the areas where at least one randomized clinical trial was published. Seven randomized controlled trials provided the evidence base; earlier phase trials also informed recommendation development. Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow examination for diagnosis of polycythemia vera (PV), according to the revised WHO criteria; the search for complementary clonal markers, such as ASXL1, EZH2, IDH1/IDH2, and SRSF2 for the diagnosis of myelofibrosis (MF) in patients who test negative for JAK2V617, CALR or MPL driver mutations. Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea. Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease; in case of intermediate-1 disease, ruxolitinib is recommended in highly symptomatic splenomegaly. Allogeneic stem cell transplantation is recommended for transplant-eligible MF patients with high or intermediate-2 risk score. Allogeneic stem cell transplantation is also recommended for transplant-eligible MF patients with intermediate-1 risk score who present with either refractory, transfusion-dependent anemia, blasts in peripheral blood > 2%, adverse cytogenetics, or high-risk mutations. In these situations, the transplant procedure should be performed in a controlled setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 4×
“A GRADE analysis of COMFORT trials documented that the overall quality of evidence supporting the benefit of ruxolitinib in reducing splenomegaly in patients with intermediate-2 or high-risk disease was high, due to the randomized design, a clear demonstration of a dose–response relationship between ruxolitinib dose a…”
MethodInfluentialGRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693 · cited 2×
“Our meta-analysis, however, failed to meet the “optimal information size” criteria: thus, we downgraded the confidence in the estimates of survival advantage of ruxolitinib for imprecision (too few events) [59].”
MethodA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Self-citationSomatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · cited 1×
“galy and amelioration of MF-related symptoms [6, 87, 88], these results challenged the primary use of hydroxyurea in this indication.”
ResultSelf-citationSomatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756 · cited 1×
“The observation that specific mutations of the calreticulin (CALR) gene are present in a significant proportion of patients with ET and MF has further expanded the knowledge of driver mutation profile providing new diagnostic and prognostic opportunities [1, 2].”
BackgroundSelf-citationCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationThe Delphi technique: a methodological discussion
Williams, P. L., & Webb, C. (1994) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.1994.tb01066.x · Cited by 929
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Self-citationRuxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Self-citationBarbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846
Self-citationBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationBarbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., et al. (2012) · Blood · doi:10.1182/blood-2012-07-444067 · Cited by 604
Self-citationKiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A., Rumi, E., Rosti, V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4886 · Cited by 552
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationPardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 485
Self-citationMesa, R. A., Kiladjian, J.-J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E. F., Deng, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4418 · Cited by 387
Self-citationPassamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.169 · Cited by 348
Self-citationGisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H.-M., Kralovics, R., & Petrides, P. E. (2013) · Blood · doi:10.1182/blood-2012-07-443770 · Cited by 330
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Self-citationMesa, R. A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J. T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M.-C., Wadleigh, M., Campbell, P. J., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.12.002 · Cited by 322
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A., Zoi, K., Reiter, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.76 · Cited by 310
Self-citationBarbui, T., Vannucchi, A. M., Buxhofer-Ausch, V, De Stefano, V, Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.94 · Cited by 283
Self-citationTefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C., Mannarelli, C., Belachew, A. A., Pancrazzi, A., Wassie, E. A., Ketterling, R. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.57 · Cited by 277
Self-citationKröger, N. M., Deeg, J. H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., Rambaldi, A., Mesa, R., Tefferi, A., Griesshammer, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.233 · Cited by 277
Self-citationPassamonti, F., Griesshammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A. M., Sivgin, S., Bensasson, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30558-7 · Cited by 260
Self-citationSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A., Laborde, R. R., Lasho, T. L., Finke, C., Begna, K., Al-Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A., Kowalski, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 233
Self-citationQuintás-Cardama, A., Abdel-Wahab, O., Manshouri, T., Kilpivaara, O., Cortes, J., Roupie, A.-L., Zhang, S.-J., Harris, D., Estrov, Z., Kantarjian, H., et al. (2013) · Blood · doi:10.1182/blood-2012-07-442012 · Cited by 218
Self-citationTefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014) · Leukemia · doi:10.1038/leu.2014.35 · Cited by 217
Self-citationGisslinger, H., Zagrijtschuk, O., Buxhofer-Ausch, V., Thaler, J., Schloegl, E., Gastl, G. A., Wolf, D., Kralovics, R., Gisslinger, B., Strecker, K., et al. (2015) · Blood · doi:10.1182/blood-2015-04-637280 · Cited by 193
Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P. J., Rumi, E., Gattoni, E., Pieri, L., Guglielmelli, P., Elena, C., et al. (2014) · Cancer · doi:10.1002/cncr.28441 · Cited by 179
Self-citationCaramazza, D., Begna, K. H., Gangat, N., Vaidya, R., Siragusa, S., Van Dyke, D. L., Hanson, C., Pardanani, A., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2010.234 · Cited by 178
Self-citationMesa, R. A., Nagorney, D. S., Schwager, S., Allred, J., & Tefferi, A. (2006) · Cancer · doi:10.1002/cncr.22021 · Cited by 177
Self-citationRuxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, C. N., Mead, A. J., Panchal, A., Fox, S., Yap, C., Gbandi, E., Houlton, A., Alimam, S., Ewing, J., Wood, M., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785790 · Cited by 174
Self-citationTefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. (2012) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 172
Self-citationLasho, T. L., Jimma, T., Finke, C. M., Patnaik, M., Hanson, C. A., Ketterling, R. P., Pardanani, A., & Tefferi, A. (2012) · Blood · doi:10.1182/blood-2012-05-429696 · Cited by 167
Self-citationAl-Ali, H. K., Griesshammer, M., le Coutre, P., Waller, C. F., Liberati, A. M., Schafhausen, P., Tavares, R., Giraldo, P., Foltz, L., Raanani, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143677 · Cited by 164
Self-citationTefferi, A., Lasho, T. L., Tischer, A., Wassie, E. A., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2014) · Blood · doi:10.1182/blood-2014-07-588426 · Cited by 161
Self-citationBarbui, T., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Rodeghiero, F., Randi, M. L., Rambaldi, A., Gisslinger, B., Pieri, L., et al. (2014) · Blood · doi:10.1182/blood-2014-07-591610 · Cited by 161
Self-citationBarbui, T., Carobbio, A., Rambaldi, A., & Finazzi, G. (2009) · Blood · doi:10.1182/blood-2009-02-206797 · Cited by 159
Self-citationVannucchi, A. M., Barbui, T., Cervantes, F., Harrison, C. N., Kiladjian, J., Kröger, N. M., Thiele, J., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv203 · Cited by 156
Self-citationAntiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Álvarez‐Larrán, A., Pereira, A., Guglielmelli, P., Hernández‐Boluda, J. C., Arellano‐Rodrigo, E., Ferrer‐Marín, F., Alimam, S., Grießhammer, M., Kerguelen, A., Andréasson, B., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.146654 · Cited by 155
Self-citationTefferi, A., Lasho, T. L., Mesa, R. A., Pardanani, A. D., Ketterling, R. P., & Hanson, C. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404711 · Cited by 124
Self-citationKomrokji, R. S., Seymour, J. F., Roberts, A. W., Wadleigh, M., To, L. B., Scherber, R. M., Turba, E., Dorr, A., Zhu, J., Wang, L., et al. (2015) · Blood · doi:10.1182/blood-2013-02-484832 · Cited by 123
Self-citationHussein, K., Pardanani, A. D., Dyke, D. L. V., Hanson, C. A., & Tefferi, A. (2009) · Blood · doi:10.1182/blood-2009-08-240135 · Cited by 121
Self-citationA phase-2 trial of low-dose pomalidomide in myelofibrosis
Begna, K. H., Mesa, R. A., Pardanani, A. D., Hogan, W. J., Litzow, M. R., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.254 · Cited by 112
Self-citationMascarenhas, J. O., Talpaz, M., Gupta, V. K., Foltz, L. M., Savona, M. R., PAQUETTE, R. L., Turner, A. R., Coughlin, P., Winton, E. F., Burn, T. C., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151126 · Cited by 112
Self-citationDoes ruxolitinib prolong the survival of patients with myelofibrosis?
Cervantes, F., & Pereira, A. (2016) · Blood · doi:10.1182/blood-2016-11-731604 · Cited by 108
Self-citationKröger, N. M., Panagiota, V., Badbaran, A., Zabelina, T., Triviai, I., Cruz, M. M. A., Shahswar, R., Ayuk, F. A., Gehlhaar, M. A., Wolschke, C., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.034 · Cited by 107
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
Barbui, T., Masciulli, A., Marfisi, M. R., Tognoni, G., Finazzi, G., Rambaldi, A., & Vannucchi, A. M. (2015) · Blood · doi:10.1182/blood-2015-04-638593 · Cited by 105
Self-citationMead, A. J., Milojković, D., Knapper, S., Garg, M. K., Chacko, J. M., Farquharson, M., Yin, J. L., Ali, S., Clark, R. E., Andrews, C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13379 · Cited by 105
Self-citationElena, C., Passamonti, F., Rumi, E., Malcovati, L., Arcaini, L., Boveri, E., Merli, M., Pietra, D., Pascutto, C., & Lazzarino, M. (2010) · Haematologica · doi:10.3324/haematol.2010.031831 · Cited by 97
Self-citationMesa, R. A., Vannucchi, A. M., Yacoub, A., Zachée, P., Garg, M. K., Lyons, R. M., Koschmieder, S., Rinaldi, C. R., Byrne, J., Hasan, Y., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14382 · Cited by 94
Self-citationPhase1/‐2 study of Pomalidomide in myelofibrosis
Mesa, R. A., Pardanani, A. D., Hussein, K., Wu, W., Schwager, S. M., Litzow, M. R., Hogan, W. J., & Tefferi, A. (2009) · American Journal of Hematology · doi:10.1002/ajh.21598 · Cited by 90
Self-citationGuglielmelli, P., Rotunno, G., Fanelli, T., Pacilli, A., Brogi, G., Calabresi, L., Pancrazzi, A., Vannucchi, A. M., & (AGIMM), O. B. O. T. A. I. P. L. R. S. C. G. I. M. M. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.90 · Cited by 88
Self-citationPRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
Duffield, J. S., & Lupher, M. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.5.1444206 · Cited by 84
Finazzi, G., Carobbio, A., Guglielmelli, P., Cavalloni, C., Salmoiraghi, S., Vannucchi, A. M., Cazzola, M., Passamonti, F., Rambaldi, A., & Barbui, T. (2014) · Blood · doi:10.1182/blood-2014-08-596676 · Cited by 82
Self-citationTefferi, A., Siragusa, S., Hussein, K., Schwager, S. M., Hanson, C. A., Pardanani, A. D., Cervantes, F., & Passamonti, F. (2009) · American Journal of Hematology · doi:10.1002/ajh.21574 · Cited by 79
Self-citationInterferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Cassinat, B., Verger, E., & Kiladjian, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1401255 · Cited by 76
Self-citationTefferi, A., Finke, C. M., Lasho, T. L., Wassie, E. A., Knudson, R. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2013) · Leukemia · doi:10.1038/leu.2013.286 · Cited by 76
Self-citationGenetic Risk Assessment in Myeloproliferative Neoplasms
Tefferi, A., & Vannucchi, A. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.06.002 · Cited by 67
Self-citationSantos, F. P. D. S., Tam, C. S. L., Kantarjian, H. M., Cortes, J. E., Thomas, D. A., Pollock, R. E., & Verstovšek, S. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.794269 · Cited by 61
Sulai, N. H., Jimma, T., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., Pardanani, A. D., & Tefferi, A. (2011) · Blood · doi:10.1182/blood.v118.21.1751.1751 · Cited by 61
Self-citationEssential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice
Tefferi, A., & Barbui, T. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.05.014 · Cited by 59
Self-citationCALR mutations and a new diagnostic algorithm for MPN
Tefferi, A., & Pardanani, A. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.16 · Cited by 58
Self-citationJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
Martí-Carvajal, A. J., Anand, V., & Solà, I. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010298.pub2 · Cited by 51
Marchetti, M., Barosi, G., Cervantes, F., Birgegård, G., Grießhammer, M., Harrison, C. N., Hehlmann, R., Kiladjian, J., Kröger, N. M., McMullin, M. F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.283 · Cited by 44
Self-citationPredictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis
Hernández‐Boluda, J. C., Correa, J. G., García‐Delgado, R., Martínez‐López, J., Álvarez‐Larrán, A., Fox, M. L., García‐Gutiérrez, V., Pérez‐Encinas, M., Ferrer‐Marín, F., Mata‐Vázquez, M. I., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12846 · Cited by 43
Self-citationGowin, K. L., Jain, T., Kosiorek, H., Tibes, R., Camoriano, J. K., Palmer, J. M., & Mesa, R. A. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.006 · Cited by 40
Self-citationReilly, J. T., McMullin, M. F., Beer, P. A., Butt, N. M., Conneally, E., Duncombe, A. S., Green, A. R., Mikhaeel, N. G., Gilleece, M. H., Knapper, S., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12985 · Cited by 38
Self-citationKvasnicka, H. M., Orazi, A., Thiele, J., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24837 · Cited by 37
Guidelines for the management of myeloproliferative neoplasms
Choi, C. W., Bang, S., Jang, S., Jung, C. W., Kim, H., Kim, H. Y., Kim, S., Kim, Y., Park, J., & Won, J.-H. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.771 · Cited by 32
Barosi, G., Vannucchi, A. M., Stefano, V. D., Pane, F., Passamonti, F., Rambaldi, A., Saglio, G. N., Barbui, T., & Tura, S. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.09.008 · Cited by 32
Self-citationDaver, N. G., Shastri, A., Kadia, T. M., Newberry, K. J., Pemmaraju, N., Jabbour, E. J., Zhou, L., Pierce, S. A., Cortes, J. E., Kantarjian, H. M., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.015 · Cited by 30
Guglielmelli, P., Pietra, D., Pane, F., Pancrazzi, A., Cazzola, M., Vannucchi, A. M., Tura, S., & Barosi, G. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.04.006 · Cited by 27
Self-citationModest activity of pomalidomide in patients with myelofibrosis and significant anemia
Daver, N. G., Shastri, A., Kadia, T. M., Quintás‐Cardama, A., Jabbour, E. J., Konopleva, M. Y., O'Brien, S. M., Pierce, S. A., Zhou, L., Cortes, J. E., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.007 · Cited by 26
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Schlenk, R. F., Stegelmann, F., Reiter, A., Jost, E., Gattermann, N., Hebart, H. F., Waller, C. F., Hochhaus, A., Platzbecker, U., Schafhausen, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.299 · Cited by 25
Self-citationBarosi, G., Rosti, V., & Gale, R. P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s31916 · Cited by 22
Self-citationRago, A., Latagliata, R., Montanaro, M., Montefusco, E., Andriani, A., Crescenzi, S. L., Mecarocci, S., Spirito, F., Spadea, A., Recine, U., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.01.001 · Cited by 13
Self-citationPractical management of myelofibrosis with ruxolitinib
Ho, P. J., Marlton, P. V., Tam, C. S. L., Stevenson, W. S., Ritchie, D., Bird, R. J., Dunlop, L. C., Durrant, S., & Ross, D. M. (2015) · Internal Medicine Journal · doi:10.1111/imj.12921 · Cited by 9
Sliwa, T., Beham‐Schmid, C., Burgstaller, S., Buxhofer‐Ausch, V., Gastl, G. A., Geissler, K. H., Krauth, M. T., Krippl, P., Lang, A. H., Petzer, A. L., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-1120-8 · Cited by 9
Metadata
- Authors
- Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., Reiter, A., Cervantes, F., Harrison, C., Mc Mullin, M. F., Hasselbalch, H. C., Koschmieder, S., Marchetti, M., Bacigalupo, A., Finazzi, G., Kroeger, N., Griesshammer, M., Birgegard, G., & Barosi, G.
- Venue
- Leukemia
- Published
- 2018-02-27
- Volume
- 32
- Issue
- 5
- Pages
- 1057-1069
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2790003237
- Cited by
- 566
- References
- 88
- FWCI
- 32.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.